Beyond mistrust: Diverse biobanking preferences among parents and adolescents with sickle cell disease.

Ninety eight percent of men diagnosed with prostate cancer (CaP) have favourable ten year survival rates as a result of improved screening, diagnosis and treatments [, ]. However they are at high risk for depression and anxiety following diagnosis and treatment, including treatment-emergent symptoms such sexual and urinary side effects []. The prevalence of comorbid depression fluctuates across cancer types, with reported rates as high as 13% in lung cancer versus 6% in genitourinary malignancies []. Estimates suggest that co-morbid depressive disorders in oncological populations are 2 to 3 times greater than in the general population []. Brunckhorst et al. [] reported a substantial psychiatric burden among men with CaP regardless of grade or stage, noting prevalence rates of 17.07% for depression, 16.86% for anxiety, and 9.85% for suicidality []. Several factors informed the study methodology. First, cognitive impairment frequently accompanies depression in older adults, affecting memory, processing speed, and executive function []. Cognitive impairments, can affect recall; [] consequently, these were assessed at baseline to ensure the validity of patient-reported outcomes—addressing an existing gap in uro-oncology literature where cognitive pre-assessments to mitigate recall bias is frequently overlooked. Second, androgen deprivation therapy (ADT) prescribed for high-risk CaP can worsen mood, including depression and anxiety []. Finally, most research has focused on North American, European, and Oceanic samples, limiting generalisability to more diverse groups and therefore this study extends current literature by examining these effects within an underrepresented sample [, ].